You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 5, 2025

Details for Patent: 4,536,516


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,536,516
Title: Alkene derivatives
Abstract:Triphenylalkene derivatives, in particular 1-(p-.beta.-dimethylaminoethyoxyphenyl)-1,2-diphenylbut-1-ene, which possess utility as anti-oestrogens.
Inventor(s): Harper; Michael J. K. (Ferney-Voltaire, FR), Richardson; Dora N. (Macclesfield, GB2), Walpole, deceased; Arthur L. (Macclesfield, GB2)
Assignee: Imperial Chemical Industries PLC (London, GB2)
Application Number:06/600,224
Patent Claim Types:
see list of patent claims
Compound; Use;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope and Claims of United States Patent 4,536,516

Introduction

United States Patent 4,536,516, hereafter referred to as the '516 patent, is a significant patent in the pharmaceutical industry, particularly related to the drug tamoxifen. This patent has been at the center of several legal and regulatory battles, especially concerning generic drug manufacturers and antitrust laws. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this patent.

Patent Overview

Publication and Expiration

The '516 patent was published on August 20, 1985, and it has since expired, with its lifetime protection ending on August 20, 2002[5].

Inventors and Assignees

The patent was originally assigned to Imperial Chemical Industries (ICI), which later transferred its rights to Zeneca Limited. Zeneca Limited is now part of AstraZeneca[2].

Subject Matter

The '516 patent pertains to alkene derivatives, specifically those used in the synthesis of tamoxifen, a drug widely used in the treatment of breast cancer. The patent describes the chemical structure and synthesis methods for these derivatives[4].

Scope and Claims

Chemical Structure

The patent describes alkene derivatives with a specific chemical formula, where R1 and R2 are both methyl, n is 2, R3 and R4 are both phenyl, and R5 is defined within certain parameters. These derivatives are crucial in the production of tamoxifen[4].

Claim Language

The patent includes multiple claims that define the scope of the invention. These claims are detailed and specify the chemical compounds, their synthesis, and their use in pharmaceutical applications. The claims are narrow enough to protect the specific invention but broad enough to encompass various methods of synthesis and application[4].

Patent Litigation and Settlements

Barr Laboratories vs. Zeneca

One of the most notable cases involving the '516 patent is the litigation between Barr Laboratories and Zeneca. Barr filed an Abbreviated New Drug Application (ANDA) with a paragraph IV certification, asserting that the '516 patent was invalid and unenforceable. This led to a patent infringement suit by ICI (later Zeneca). The case was eventually settled in 1993, with Barr withdrawing its challenge to the patent's validity and Zeneca paying Barr $21 million and licensing Barr to sell tamoxifen manufactured by Zeneca[2].

Antitrust Implications

The settlement between Zeneca and Barr raised antitrust concerns. The court of appeals held that the settlement was valid under antitrust laws, reasoning that the patent holder was entitled to protect its lawful monopoly over the patented product. However, Judge Pooler dissented, arguing that the standard of liability was insufficiently protective of consumer interests and that the settlement's reasonableness should be evaluated based on the strength of the patent and the amount paid to the generic manufacturer[1].

Regulatory Framework

Hatch-Waxman Act

The '516 patent case is intricately linked with the Hatch-Waxman Act, which aims to balance the interests of brand-name drug manufacturers and generic drug manufacturers. The Act allows generic manufacturers to file ANDAs with paragraph IV certifications, challenging the validity or enforceability of the patent. This led to the litigation and subsequent settlement between Zeneca and Barr[2][5].

FDA Approval Process

The FDA's approval process for generic drugs, as outlined in the Hatch-Waxman Act, played a crucial role in the '516 patent case. The Act allows for a 30-month stay of FDA approval for the generic drug while patent litigation is ongoing. In the case of Mylan Pharmaceuticals, the FDA converted the approval status of Mylan's ANDA from final to tentative approval pending the expiration of the '516 patent[5].

Impact on the Pharmaceutical Industry

Generic Drug Entry

The '516 patent case highlights the challenges generic drug manufacturers face when entering the market. The settlement between Zeneca and Barr delayed the entry of generic tamoxifen, illustrating how patent litigation and settlements can affect market competition and consumer access to affordable drugs[2].

Antitrust Considerations

The case also underscores the importance of antitrust laws in regulating settlements between brand-name and generic drug manufacturers. The dissenting opinion by Judge Pooler emphasizes the need for a more stringent standard to protect consumer interests and ensure that settlements do not extend the patent monopoly beyond its legitimate scope[1].

Key Takeaways

  • Patent Scope: The '516 patent is specific to alkene derivatives used in tamoxifen synthesis, with detailed claims protecting the chemical compounds and their synthesis methods.
  • Litigation and Settlements: The patent was involved in significant litigation and settlements, particularly between Zeneca and Barr, which raised antitrust concerns.
  • Regulatory Framework: The Hatch-Waxman Act plays a crucial role in balancing the interests of brand-name and generic drug manufacturers, influencing the approval process and patent litigation.
  • Industry Impact: The case affects the timing and cost of generic drug entry, highlighting the tension between patent protection and antitrust laws.

FAQs

What is the '516 patent related to?

The '516 patent is related to alkene derivatives used in the synthesis of tamoxifen, a drug for treating breast cancer.

Who were the key parties involved in the litigation over the '516 patent?

The key parties involved were Zeneca Limited (successor to ICI) and Barr Laboratories.

What was the outcome of the settlement between Zeneca and Barr?

The settlement involved Barr withdrawing its challenge to the patent's validity, Zeneca paying Barr $21 million, and licensing Barr to sell tamoxifen manufactured by Zeneca.

How does the Hatch-Waxman Act impact the '516 patent case?

The Hatch-Waxman Act allows generic manufacturers to file ANDAs with paragraph IV certifications, challenging the patent's validity, and provides for a 30-month stay of FDA approval during patent litigation.

What are the antitrust implications of the '516 patent case?

The case raised concerns about whether the settlement between Zeneca and Barr extended the patent monopoly beyond its legitimate scope, with Judge Pooler arguing for a more stringent standard to protect consumer interests.

Sources

  1. Brief for the United States as Amicus Curiae: Betty Joblove, et al. v. Barr Laboratories, Inc. - Justice Department.
  2. In re Tamoxifen Citrate Antitrust Litigation - Federal Cases - Case Law.
  3. Patent Claims and Patent Scope - Hoover Institution.
  4. US4536516A - Alkene derivatives - Google Patents.
  5. ANDA 74-732 March 21, 2002 Mylan Pharmaceuticals, Inc. - FDA.

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 4,536,516

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

Foreign Priority and PCT Information for Patent: 4,536,516

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom34989/62Sep 13, 1962
United Kingdom30755/65Jul 20, 1965

International Family Members for US Patent 4,536,516

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Belgium 637389 ⤷  Subscribe
Belgium 678807 ⤷  Subscribe
Brazil 6352734 ⤷  Subscribe
Brazil 6678265 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 4 of 4 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.